Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Microbiol Spectr
2023 Aug 17;114:e0139323. doi: 10.1128/spectrum.01393-23.
Show Gene links
Show Anatomy links
The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro, In Vivo, and In Silico Studies of Macromolecular Targets.
Roquini V
,
Mengarda AC
,
Cajas RA
,
Martins-da-Silva MF
,
Godoy-Silva J
,
Santos GA
,
Espírito-Santo MCC
,
Pavani TFA
,
Melo VA
,
Salvadori MC
,
Teixeira FS
,
Rando DGG
,
de Moraes J
.
???displayArticle.abstract???
Schistosomiasis is a parasitic disease that afflicts approximately 250 million people worldwide. There is an urgent demand for new antiparasitic agents because praziquantel, the only drug available for the treatment of schistosomiasis, is not universally effective and may derail current progress toward the WHO goal of eliminating this disease as a public health problem by 2030. Nifuroxazide (NFZ), an oral nitrofuran antibiotic, has recently been explored to be repurposed for parasitic diseases. Here, in vitro, in vivo, and in silico studies were conducted to evaluate the activity of NFZ on Schistosoma mansoni. The in vitro study showed significant antiparasitic activity, with 50% effective concentration (EC50) and 90% effective concentration (EC90) values of 8.2 to 10.8 and 13.7 to 19.3 μM, respectively. NFZ also affected worm pairing and egg production and induced severe damage to the tegument of schistosomes. In vivo, a single oral dose of NFZ (400 mg/kg of body weight) to mice harboring either prepatent or patent S. mansoni infection significantly reduced the total worm burden (~40%). In patent infection, NFZ achieved a high reduction in the number of eggs (~80%), but the drug caused a low reduction in the egg burden of animals with prepatent infection. Finally, results from in silico target fishing methods predicted that serine/threonine kinases could be one of the potential targets for NFZ in S. mansoni. Overall, the present study revealed that NFZ possesses antischistosomal properties, mainly in terms of egg burden reduction in animals with patent S. mansoni infection. IMPORTANCE The increasing recognition of the burden imposed by helminthiasis, associated with the limited therapeutic arsenal, has led to initiatives and strategies to research and develop new drugs for the treatment of schistosomiasis. One of these strategies is drug repurposing, which considers low-risk compounds with potentially reduced costs and shorter time for development. In this study, nifuroxazide (NFZ) was evaluated for its anti-Schistosoma mansoni potential through in vitro, in vivo, and in silico studies. In vitro, NFZ affected worm pairing and egg production and induced severe damage to the tegument of schistosomes. In vivo, a single oral dose of NFZ (400 mg/kg) to mice harboring either prepatent or patent S. mansoni infection significantly reduced the total worm burden and egg production. In silico investigations have identified serine/threonine kinases as a molecular target for NFZ. Collectively, these results implied that NFZ might be a potential therapeutic candidate for the treatment of schistosomiasis.
Althagafy,
Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms.
2023, Pubmed
Althagafy,
Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms.
2023,
Pubmed
Altschul,
Basic local alignment search tool.
1990,
Pubmed
Amorim,
Schiff bases of 4-Phenyl-2-Aminothiazoles as hits to new antischistosomals: Synthesis, in vitro, in vivo and in silico studies.
2020,
Pubmed
Assaré,
Characteristics of persistent hotspots of Schistosoma mansoni in western Côte d'Ivoire.
2020,
Pubmed
Bailly,
Toward a repositioning of the antibacterial drug nifuroxazide for cancer treatment.
2019,
Pubmed
Begovic,
Open Clinical Trial on Using Nifuroxazide Compared to Probiotics in Treating Acute Diarrhoeas in Adults.
2016,
Pubmed
Bergquist,
Artemether and Praziquantel: Origin, Mode of Action, Impact, and Suggested Application for Effective Control of Human Schistosomiasis.
2018,
Pubmed
Blumenstiel,
Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase.
1999,
Pubmed
Bourée,
[Double-blind controlled study of the efficacy of nifuroxazide versus placebo in the treatment of acute diarrhea in adults].
1989,
Pubmed
Brito,
Neolignans isolated from Saururus cernuus L. (Saururaceae) exhibit efficacy against Schistosoma mansoni.
2022,
Pubmed
,
Echinobase
Ceruti,
Development and Validation of a HPLC-MS/MS Method to Measure Nifuroxazide and Its Application in Healthy and Glioblastoma-Bearing Mice.
2022,
Pubmed
Cioli,
Praziquantel.
2003,
Pubmed
Colley,
Human schistosomiasis.
2014,
Pubmed
Coulibaly,
Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.
2017,
Pubmed
Deol,
Schistosomiasis - Assessing Progress toward the 2020 and 2025 Global Goals.
2019,
Pubmed
Ferreira,
Approaches to advance drug discovery for neglected tropical diseases.
2022,
Pubmed
Gan,
Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.
2022,
Pubmed
Guerra,
In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing.
2019,
Pubmed
Guimarães,
Epiisopilosine alkaloid has activity against Schistosoma mansoni in mice without acute toxicity.
2018,
Pubmed
Hui,
Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.
2015,
Pubmed
Ismail,
Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.
1996,
Pubmed
Janes,
The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.
2018,
Pubmed
Jesudoss Chelladurai,
Praziquantel Resistance in the Zoonotic Cestode Dipylidium caninum.
2018,
Pubmed
Kaiser,
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.
2015,
Pubmed
Kayamba,
Lactate dehydrogenase and malate dehydrogenase: Potential antiparasitic targets for drug development studies.
2021,
Pubmed
Labaune,
Comparative physiological disposition of two nitrofuran anti-microbial agents.
1986,
Pubmed
Lago,
Phenotypic screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the treatment of schistosomiasis.
2019,
Pubmed
Lago,
Antischistosomal agents: state of art and perspectives.
2018,
Pubmed
Liu,
Chemical markers' fishing and knockout for holistic activity and interaction evaluation of the components in herbal medicines.
2010,
Pubmed
McCrudden,
Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases.
2000,
Pubmed
McManus,
Schistosomiasis.
2018,
Pubmed
Mengarda,
Recent trends in praziquantel nanoformulations for helminthiasis treatment.
2022,
Pubmed
Mengarda,
Recent approaches in nanocarrier-based therapies for neglected tropical diseases.
2023,
Pubmed
Mengarda,
Antiparasitic activity of piplartine (piperlongumine) in a mouse model of schistosomiasis.
2020,
Pubmed
Mengarda,
Licarin A, a neolignan isolated from Nectandra oppositifolia Nees & Mart. (Lauraceae), exhibited moderate preclinical efficacy against Schistosoma mansoni infection.
2021,
Pubmed
Nelson,
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
2008,
Pubmed
Pereira Moreira,
Drug Repurposing and De Novo Drug Discovery of Protein Kinase Inhibitors as New Drugs against Schistosomiasis.
2022,
Pubmed
Porto,
Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni.
2021,
Pubmed
Probst,
Improving translational power in antischistosomal drug discovery.
2022,
Pubmed
Pushpakom,
Drug repurposing: progress, challenges and recommendations.
2019,
Pubmed
Rando,
Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.
2008,
Pubmed
Rando,
Vanillin-Related N-Acylhydrazones: Synthesis, Antischistosomal Properties and Target Fishing Studies.
2019,
Pubmed
,
Echinobase
Rando,
Potential tuberculostatic agents. Topliss application on benzoic acid [(5-nitro-thiophen-2-yl)-methylene]-hydrazide series.
2002,
Pubmed
Roquini,
Susceptibility of Angiostrongylus cantonensis Larvae to Anthelmintic Drugs.
2022,
Pubmed
Roquini,
Promethazine exhibits antiparasitic properties in vitro and reduces worm burden, egg production, hepato-, and splenomegaly in a schistosomiasis animal model.
2019,
Pubmed
Scarpignato,
Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach.
1995,
Pubmed
Sessa,
15β-Senecioyl-oxy-ent-kaur-16-en-19-oic Acid, a Diterpene Isolated from Baccharis lateralis, as Promising Oral Compound for the Treatment of Schistosomiasis.
2020,
Pubmed
Silva,
Antischistosomal activity of the terpene nerolidol.
2014,
Pubmed
Silva,
Brazilian red propolis exhibits antiparasitic properties in vitro and reduces worm burden and egg production in an mouse model harboring either early or chronic Schistosoma mansoni infection.
2021,
Pubmed
Singh,
Visceral schistosomiasis of domestic animals in India: humoral immune status of infected cattle, sheep and goats against major polypeptide antigens of Schistosoma indicum and S. spindale.
2004,
Pubmed
Webster,
Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns.
2013,
Pubmed
Wiegand,
A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.
2017,
Pubmed
Xavier,
H1-antihistamines as antischistosomal drugs: in vitro and in vivo studies.
2020,
Pubmed
Xavier,
Therapeutic Efficacy of Carvacrol-Loaded Nanoemulsion in a Mouse Model of Schistosomiasis.
2022,
Pubmed
Yang,
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model.
2015,
Pubmed
da Costa,
Trypanosoma cruzi trans-Sialidase as a Potential Vaccine Target Against Chagas Disease.
2021,
Pubmed
de Almeida,
Flavonoids and Sesquiterpene Lactones from Artemisia absinthium and Tanacetum parthenium against Schistosoma mansoni Worms.
2016,
Pubmed
de Brito,
Therapeutic Effect of Diminazene Aceturate on Parasitic Blood Fluke Schistosoma mansoni Infection.
2020,
Pubmed
de Carvalho,
ATP-Diphosphohydrolases in Parasites: Localization, Functions and Recent Developments in Drug Discovery.
2019,
Pubmed
de Moraes,
FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?
2020,
Pubmed
de Moraes,
In vitro synergistic interaction between amide piplartine and antimicrobial peptide dermaseptin against Schistosoma mansoni schistosomula and adult worms.
2013,
Pubmed
de Moraes,
Antischistosomal Activity of Oxindolimine-Metal Complexes.
2015,
Pubmed